Business unit Vifor Pharma

Key figures 2016

Net sales

CHF 1,167.0 million

EBITDA

CHF 330.9 million

EBIT

CHF 245.2 million

ROS

21.0%

Investments

CHF 269.6 million

Employees

2,487 (2,410 full-time equivalents)

 

Highlights of 2016

  • Vifor Pharma reinforced its global leadership in iron deficiency and simultaneously ensured market expansion.
  • The US biopharmaceutical company Relypsa was acquired and integrated into Vifor Pharma, further strengthening Vifor Pharma’s product portfolio by obtaining global rights to Veltassa® (US brand name), a potassium binder for the treatment of hyperkalaemia.
  • Vifor Fresenius Medical Care Renal Pharma (VFMCRP), our common company with Fresenius Medical Care, reinforced its position as a leading player in nephrology.

39.3 %

sales increase of Ferinject®/ Injectafer®


Outlook for 2017

  • Establish Vifor Pharma as an independent, global specialty pharmaceutical company following the IPO of Galenica Santé.
  • Enhance Vifor Pharma’s global footprint while remaining true to its Swiss roots.
  • Continue to increase the confidence of private and institutional shareholders.
  • Expand the iron market, especially in the USA, by further increasing awareness around iron deficiency.
  • Reinforce VFMCRP’s position as a leading player in nephrology in close cooperation with our partner Fresenius Medical Care.
  • Combine commercial assets and best-in-class cardio-renal products of Vifor Pharma, Relypsa and VFMCRP to become a major player.

Contact

Galenica Ltd.

Untermattweg 8
CH-3027 Bern

Phone:
+41 58 852 81 11
Fax:
+41 58 852 81 12

Send link

Send as link



Links

  •